BACTERIA ISOLATION FROM STOOLS COLLECTED FROM CENTENARIANS PEOPLE

NCT ID: NCT05701371

Last Updated: 2024-03-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-06

Study Completion Date

2023-10-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The compositional analysis of commensal bacterial populations collected from a variety of clinical samples has been recently made possible with the availability of Next Generation Sequencing (NGS) technologies. The term 'next-generation probiotics' (NGP) is now widely used to describe these commensal species of potential health interest. However, this approach is still hampered by the fact that there are usually few or even no strains available for a number of commensal species. In this context, BIOASTER has developed a specific technological process based on flow cytometry analysis and then sorting under strictly anaerobic conditions to target and cultivate commensal species of interest.

The review of the literature shows that certain species present among centenarians have an interest in maintaining the longevity of these individuals. Numerous studies have shown that the intestinal microbiota of centenarians presents a greater diversity compared to groups of younger subjects as well as an enrichment in certain bacteria such as Akkermansia and Christensenella.

The goal of this observational study is to constitute a biological samples collection from centenarian people, to proceed with the isolation of beneficial commensal strains such as Faecalibacterium prausnitzii, Akkermansia muciniphila and Oscillospiraceae, in a non-limitative way.

Elderly and centenarian people will be recruited in nursing home among the Gerontopole of "Ile de France" network.

Blood (serum + TruCulture tubes) and stools will be collected from each subject.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Centenarian cohort

Biological samples collection

Intervention Type OTHER

blood drawing + feces collection in a dedicated device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biological samples collection

blood drawing + feces collection in a dedicated device

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 95 years and older
* BMI between 18.5 and 25 kg/m2
* Clinical exam normal
* Subject agreeing to participate in the study and not objecting to participate in the study.
* Able and willing to provide samples of blood and faeces

Exclusion Criteria

* Diagnosed acute or chronic gastrointestinal disease or complication (e.g., celiac disease, gastroesophageal reflux, gastric or duodenal ulcer, Crohn's disease, hemorrhoids, irritable bowel syndrome)
* Infectious gastrointestinal event within 3 months prior to inclusion
* Diabetes
* Severe chronic disease (active cancer, HIV, severe renal failure, ongoing severe heart or liver or biliary disorders, arthritis) or severe chronic disease deemed incompatible with the conduct of the study by the investigator
* Major surgical procedure likely to disrupt the intestinal microbiota, within 6 months prior to inclusion
* Recent food allergy \< 3 months prior to inclusion
* Antibiotic, antiviral, antifungal, proton pump inhibitor or any other treatment likely to disrupt the microbiota in the 3 months prior to inclusion
* Previous or current use of a treatment that may disrupt the microbiota (e.g. laxatives, antidiarrheals, antacids...) in the last 3 months
* Significant change in dietary habits or physical activities in the 3 months prior to inclusion
* Consumption of more than 2 standard glasses of alcoholic beverages per day
* Smoking \> 20 cigarettes per day, illicit drug use,
* Daily use of non-steroidal anti-inflammatory drugs (NSAIDs)
* Severe psychiatric or neurological pathology
* Completely dependent subject (GIR Score = 1)
* Subject with liquid stools (Bristol Score = 7) or very hard stools (Bristol Score = 1)
* Vaccination in the last month before inclusion
* Subject unable to understand the purpose of the research, answer questions and give their decision to participate in the study
* Subject already included in another research study involving the human subject
* Subject under guardianship and whose guardianship objects to the participation of his/her protectee,
* Subject not affiliated with a social security plan or not a beneficiary of such a plan
Minimum Eligible Age

95 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bioaster

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cyril GUYARD

Role: STUDY_DIRECTOR

Bioaster

Olivier HANON

Role: PRINCIPAL_INVESTIGATOR

Gérond'if

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gerond'if - Gérontopôle Ile de France

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-A02293-40

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Probiotic Detection and Persistence Study
NCT04065503 COMPLETED EARLY_PHASE1